Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish

Behavioural Brain Research

Volumn 217, Issue 1, 2011, Pages 10-15

  Richetti, S K ^a,b   Blank, M ^a,b   Capiotti, K M ^a,b   Piato, A L ^a,b   Bogo, M R ^a,b   Vianna, M R ^a,b   Bonan, C D ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina INCT TM   (Brazil)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Quercetin; Rutin; Scopolamine; Zebrafish

Indexed keywords

QUERCETIN; RUTOSIDE; SCOPOLAMINE;

ADULT ANIMAL; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LOCOMOTION; MALE; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ZEBRA FISH;

ANIMALS; ANTIOXIDANTS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; MALE; MEMORY DISORDERS; MOTOR ACTIVITY; QUERCETIN; RUTIN; SCOPOLAMINE; ZEBRAFISH;

EID: 78149273255     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.09.027     Document Type: Article

References (66)

1. Ahmed T., Gilani A.-H. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 2009, 91:554-559.
2. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement 2010, 6(2):158-194.
3. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217(4558):408-414.
4. Best J.D., Alderton W.K., Zebrafish An in vivo model for the study of neurological diseases. Neuropsychiatr Dis Treat 2008, 4(3):567-576.
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, 1:CD005593.
6. Blank M., Guerim L.D., Cordeiro R.F., Vianna M.R. A one-trial inhibitory avoidance task to zebrafish: rapid acquisition of an NMDA-dependent long-term memory. Neurobiol Learn Mem 2009, 92(4):529-534.
7. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
8. Braganhol E., Tamajusuku A.S., Bernardi A., Wink M.R., Battastini A.M. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim Biophys Acta 2007, 1770(9):1352-1359.
9. Casey D.A., Antimisiaris D., O'Brien J. Drugs for Alzheimer's disease: are they effective?. P&T 2010, 35(4):208-211.
10. Conseil G., Baubichon-Cortay H., Dayan G., Jault J.M., Barron D., Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP and steroid binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998, 95:9831-9836.
11. Crawford A.D., Esguerra C.V., de Witte P.A.M. Fishing for Drugs from nature: zebrafish as a technology platform for natural product discovery. Planta Med 2008, 74:624-632.
12. Deutsch J.A. The cholinergic synapse and the site of memory. Science 1971, 174:788-794.
13. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 2002, 14:93-126.
14. Flood J.F., Landry D.W., Jarvik M.E. Cholinergic receptor interactions and their effects on long-term memory processing. Brain Res 1981, 215:177-185.
15. Gerlai R. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. Molecules 2010, 15(4):2609-2622.
16. Gerlai R. Zebrafish: an uncharted behavior genetic model. Behav Genet 2003, 33:461-468.
17. Gerlai R., Lahav M., Guo S., Rosenthal A. Drinks like a fish: zebra fish (Danio rerio) as a behavior genetic model to study alcohol effects. Pharmacol Biochem Behav 2000, 67:773-782.
18. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003, 28:515-522.
19. Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Curr Opin Pharmacol 2004, 4(5):504-512.
20. Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?. Genes Brain Behav 2004, 3:63-74.
21. Han C.K., Park Y.H., Jin D.Q., Hwang Y.K., Oh K.B., Han J.S. SK-PC-B70M from Pulsatilla koreana improves scopolamine-induced impairments of memory consolidation and spatial working memory. Brain Res 2007, 1184:254-259.
22. Harvsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 2002, 96:67-202.
23. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006, 16(6):710-715.
24. Horvathova K., Novotny L., Vachalkova A. The free radical scavenging activity of four flavonoids determined by the comet assay. Neoplasma 2003, 50:291-295.
25. Ji H.F., Zhang H.Y. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. J Mol Struct 2006, 767:3-9.
26. Kavutcu M., Melzig M.F. In vitro effects of selected flavonoids on the 5-nucleotidase activity. Pharmazie 1999, 54:457-459.
27. Kim D.H., Yoon B.H., Kim Y.W., Lee S., Shin B.Y., Jung J.W., et al. The seed extract of Cassia obtusifolia ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. J Pharmacol Sci 2007, 105:82-93.
28. Kim M.J., Choi S.J., Lim S.T., Kim H.K., Kim Y.J., Yoon H.G., et al. Zeatin supplement improves scopolamine-induced memory impairment in mice. Biosci Biotechnol Biochem 2008, 72(2):577-581.
29. Kim Y.H., Lee Y., Kim D., Jung M.W., Lee C.J. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. Neurosci Res 2010, 67(2):156-161.
30. Lee Y., Kim D., Kim Y.H., Lee H., Lee C.J. Improvement of pentylenetetrazol-induced learning deficits by valproic acid in the adult zebrafish. Eur J Pharmacol 2010, 643(2-3):225-231.
31. Kinsella K, Wan H. "An Ageing World" US Census Bureau, International Population Reports. Washington, DC: US Government Printing Office; 2009. P95/09-1.
32. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010, 34(8):1307-1350.
33. Lieschke G.J., Currie P.D. Animal models of human disease: zebrafish swim into view. Nat Rev Genet 2000, 8(5):353-367.
34. Maggini M., Vanacore N., Raschetti R. Cholinesterase inhibitors: drugs looking for a disease?. PLoS Med 2006, 3(4):e140.
35. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
36. Miklosi A., Andrew R.J. The zebrafish as a model for behavioral studies. Zebrafish 2006, 3:227-234.
37. Mount C., Downton C. Alzheimer disease: progress or profit?. Nat Med 2006, 12:780-784.
38. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009, 461:895-897.
39. Paquet D., Schmid B., Haass C. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo. Neurodegener Dis 2010, 7(1-3):99-102.
40. Park S.Y., Bok S.H., Jeon S.M., Park Y.B., Lee S.J., Jeong T.S., et al. Effect of Rutin and tannic acid supplements on cholesterol metabolism in rats. Nutr Res 2002, 22:283-295.
41. Park Y.C., Rimbach G., Saliou C., Valacchi G., Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF-α secretion, and NF-κB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett 2000, 464:93-97.
42. Phelps H.A., Runft D.L., Neely M.N. Adult zebrafish model of streptococcal infection. Curr Protocol Microbiol 2009, 9D.1.1-9D.1.27.
43. Power A.E., Vazdarjanova A., McGaugh J.L. Muscarinic cholinergic influences in memory consolidation. Neurobiol Learn Mem 2003, 80(178):193.
44. Pu F., Mishima K., Irie K., Motohashi K., Tanaka Y., Orito K., et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci 2007, 104(4):329-334.
45. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006, 545:51-64.
46. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 2007, 9(10):1647-1658.
47. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781-784.
48. Roger M.L., Miia K., Nigel H.G. Acetylcholinesterase and its inhibition in Alzheimer's disease. Clin Neuropharmacol 2004, 27:141-149.
49. Ross J.A., Kasum C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002, 22:19-34.
50. Rossi L., Mazzitelli S., Arciello M., Capo C.R., Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res 2008, 33:2390-2400.
51. Rubinstein A.L. Zebrafish: from disease modelling to drug discovery. Cur Opin Drug Discov Devel 2003, 6:218-223.
52. Shanno R.L. Rutin: a new drug for the treatment of increased capillary fragility. Am J Med Sci 1946, 211:539-543.
53. Sheu J.R., Hsiao G., Chou P.H., Shen M.Y., Chou D.S. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonols quercetin, in human platelets. J Agric Food Chem 2004, 52:4414-4418.
54. Singh M., Arseneault M., Sanderson T., Murthy V., Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008, 56:4855-4873.
55. Spencer J.P. Flavonoids: modulators of brain function?. Br J Nutr 2008, 99E(Suppl 1):ES60-77.
56. Spencer J.P. The impact of flavonoids on memory: physiological and molecular considerations. Chem Soc Rev 2009, 38(4):1152-1161.
57. Spencer J.P., Abd El Mohsen M.M., Minihane A.M., Mathers J.C. Biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research. Br J Nutr 2008, 99(1):12-22.
58. Spencer J.P., Vauzour D., Rendeiro C. Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. Arch Biochem Biophys 2009, 492(1-2):1-9.
59. Stratton L.O., Petrinovich L. Post-trial injections of an anti-cholinesterase drug and maze learning in two strains of rats. Psychopharmacology 1963, 5:47-54.
60. Tinsley M.R., Quinn J.J., Fanselow M.S. The role of muscarinic and nicotinic cholinergic neurotransmission in aversive conditioning: comparing pavlovian fear conditioning and inhibitory avoidance. Learn Mem 2004, 11:35-42.
61. Vafeiadou K., Vauzour D., Spencer J.P. Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets 2007, 7(3):211-224.
62. Wang H., Lu Y., Chen H.Z. Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice. Neurosci Lett 2003, 344:173-176.
63. Ward C.P., Redd K., Williams B.M., Caler J.R., Luo Y., McCoy J.G. Ginkgo biloba extract: cognitive enhancer or antistress buffer. Pharmacol Biochem Behav 2002, 72:913-922.
64. Weinberger N.M. Food for thought: honeybee foraging, memory, and acetylcholine. Sci STKE 2006, 336:e23.
65. Xiang X.H., Wang H.L., Wu W.R., Guo Y., Cao D.Y., Wang H.S., et al. Ethological analysis of scopolamine treatment or pretreatment in morphine dependent rats. Physiol Behav 2006, 88:183-189.
66. Zhang W.W., Song M.K., Cui Y.Y., Wang H., Zhu L., Niu Y.Y., Lu Y., et al. Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine. Neurosci Lett 2008, 443:241-245.